

Robert A Copeland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3304264/publications.pdf>

Version: 2024-02-01

20
papers

5,358
citations

567281

15
h-index

839539

18
g-index

25
all docs

25
docs citations

25
times ranked

8081
citing authors

#	ARTICLE	IF	CITATIONS
1	Drugâ€™target residence time and its implications for lead optimization. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 730-739.	46.4	1,237
2	Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 20980-20985.	7.1	608
3	The drugâ€™target residence time model: a 10-year retrospective. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 87-95.	46.4	540
4	Residence Time of Receptorâ€™Ligand Complexes and Its Effect on Biological Function. <i>Biochemistry</i> , 2008, 47, 5481-5492.	2.5	469
5	Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in <i>EZH2</i> -Mutant Non-Hodgkin Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 842-854.	4.1	457
6	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. <i>Lancet Oncology</i> , The, 2018, 19, 649-659.	10.7	450
7	Mechanistic considerations in high-throughput screening. <i>Analytical Biochemistry</i> , 2003, 320, 1-12.	2.4	151
8	A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 7625-7630.	7.1	112
9	RNA-modifying proteins as anticancer drug targets. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 435-453.	46.4	107
10	Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis. <i>Analytical Biochemistry</i> , 2011, 416, 206-210.	2.4	82
11	Mechanism of Inhibition of Human KSP by Monastrol: Insights from Kinetic Analysis and the Effect of Ionic Strength on KSP Inhibition. <i>Biochemistry</i> , 2004, 43, 15258-15266.	2.5	52
12	Drug Discovery and Chemical Biology of Cancer Epigenetics. <i>Cell Chemical Biology</i> , 2017, 24, 1120-1147.	5.2	47
13	Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2018, 373, 20170080.	4.0	34
14	Reaction Coupling between Wild-Type and Disease-Associated Mutant EZH2. <i>ACS Chemical Biology</i> , 2014, 9, 2459-2464.	3.4	29
15	Evolution of the drug-target residence time model. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1441-1451.	5.0	25
16	The Elements of Translational Chemical Biology. <i>Cell Chemical Biology</i> , 2018, 25, 128-134.	5.2	16
17	A method for determining intracellular concentrations of enzyme substrates from a combination of competitive inhibition and mutagenesis studies. <i>Analytical Biochemistry</i> , 2005, 337, 351-353.	2.4	2
18	Chance Favors the Perplexed Mind: The Critical Role of Mechanistic Biochemistry in Drug Discovery. <i>Biochemistry</i> , 2021, 60, 2275-2284.	2.5	2

#	ARTICLE	IF	CITATIONS
19	Special Issue on Epigenetics: Targeting Chromatin- and RNA- Modifications. ACS Medicinal Chemistry Letters, 2020, 11, 2051-2052.	2.8	0
20	A Second p53 Binding Site in the Central Domain of Mdm2 Is Essential for p53 Ubiquitination. FASEB Journal, 2007, 21, A273.	0.5	0